Can this soaring biotech penny share make me rich?

This penny share has surged 1,200% in the last two years. Am I too late now, or are there still big profits for me to make?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in e-Therapeutics (LSE: ETX) have climbed 65% in 2021. And, over the past two years, we’re looking at a gain of over 1,200%. Before that, e-Therapeutics really was a penny share, trading at around 2p. Even today, at 29p, I’d say it still fits the description.

The company released full-year results Thursday. But before I examine them, what does it do? Well, e-Therapeutics is developing AI-based software aimed at speeding up the drug delivery business. The technology is being used to investigate diabetes, Alzheimer’s, Parkinson’s, and other ailments. But what about Covid-19, which has clearly driven the penny share price gains?

The results speak of e-Therapeutics’ new Covid project. It’s using its technology “to identify approved and known drugs, both alone and as synergistic combinations, that could rapidly be repositioned for the treatment of Covid-19.”

That illustrates a key thing I like about the e-Therapeutics drug discovery platform. It’s based on artificial intelligence, analysing existing data to find novel applications for drugs that have already been through the lengthy approvals process. It appears flexible and can be adapted to new ailments relatively quickly. So that’s a definite positive for me. But is it enough for me to buy a penny share?

Show me the balance sheet

No. Technological promise alone will not get me to invest. I’ll only buy if I think a firm’s financial situation stacks up too. I’m also very wary of going for a penny share because I’m painfully aware that most of them got that way by previously commanding higher prices and then collapsing. And that did, in fact, happen at e-Therapeutics. On flotation day back in 2007, the shares were placed at 67p apiece.

The company reported an operating loss of £4.5m for the year to 31 January, after a R&D spend of £2.7m. That’s on rather modest revenue of £0.3m. So, still very much in the cash-burn phase. The year, in financial terms, was very much a fundraising one, in which “the company strengthened its financial position raising total gross funds of £13.2m.”

The biggest equity issue, of £11.6m, happened in July 2020. With the pandemic in full swing, it was clearly a good time to tap the markets for cash. It’s led to a healthy balance sheet, with cash of £13m on the books at 31 January. The huge share price rise, however, has pushed its market capitalisation to £117m. With no profits yet, that implies investors see the future value of that £13m cash rising ninefold.

Will I buy a penny share?

So, will I put my penny share aversion to one side and buy e-Therapeutics shares? In short, no. Not now. I do think I’m seeing some exciting potential in the company’s technology. And the urgency that the current pandemic has forced on the drug discovery and development process can only highlight the value of this technological approach.

I just think the current share price puts too high a value on that potential and leaves little or no safety room to allow for the risks. The main risk I see is that it will take longer then expected to reach sustainable profits, which could result in a share price reversal. If that happens though, I’ll be rethinking it.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »